Choose Your Country or Region

RGFP966

Catalog No.S7229 Purity:99.74%

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.

RGFP966 Chemical Structure

CAS No. 1396841-57-8

Purity & Quality Control

Batch: Purity: 99.74%

99.74

Products often used together with RGFP966

Tubastatin A

RGFP966 and Tubastatin A decrease total HDAC activity in HLMVEC and reduce the inflammatory and hyper-permeability response to LPS in mice.

Birmpas C, et al. The FASEB Journal 29 (2015): 411-4.

(+)-JQ1

RGFP966 and JQ1 dramatically reduces tumor volume and growth rate and suppresses tumor growth via induction of apoptosis in the glioma xenograft mouse model.

Wang Q, et al. Mol Cancer Ther. 2020 Dec;19(12):2542-2553.

TSA (Trichostatin A)

RGFP966 and Trichostatin A increases the expression of AKAP12 at both the mRNA and protein levels.

He P, et al. Int J Oncol. 2018 Apr;52(4):1305-1316.

RGFP966 Related Products

Related Targets	HDAC1 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HDAC10 HDAC11 HD1 HD2	Click to Expand
Related Products	Entinostat (MS-275) TSA (Trichostatin A) Mocetinostat (MGCD0103) Tubastatin A Ricolinostat (ACY-1215) Quisinostat (JNJ-26481585) 2HCl MC1568 Tubastatin A HCl PCI-34051 Tacedinaline (CI994) LMK-235 Fimepinostat (CUDC-907) Tubacin Givinostat (ITF2357) TMP269 AR-42 Sodium butyrate Pracinostat (SB939) Santacruzamate A (CAY10683) Abexinostat (PCI-24781) (-)-Parthenolide CUDC-101 Dacinostat (LAQ824) CAY10603 RG2833 (RGFP109) Tasquinimod Tucidinostat (Chidamide) TMP195 Nexturastat A Droxinostat Domatinostat (4SC-202) Scriptaid 4-PBA (4-Phenylbutyric acid) M344 Resminostat Citarinostat (ACY-241) BG45 WT161 ACY-738 HPOB ITSA-1 (ITSA1) Tubastatin A TFA TC-H 106 SIS17 ACY-775 BML-210 (CAY10433) TH34 Raddeanin A	Click to Expand
Related Compound Libraries	Kinase Inhibitor Library FDA-approved Drug Library Natural Product Library Bioactive Compound Library-I Highly Selective Inhibitor Library	Click to Expand

Signaling Pathway

HDAC Signaling Pathway

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
APL cells	Function assay	≤2 μM	48 h	DMSO	RGFP966 did not induce apoptosis in APL cells but did reduce clonogenicity and increased maturation.	26447190
Em-Myc lymphoma cells	Function assay	≤1 μM	48 h	DMSO	Cell proliferated significantly more slowly than vehicle-treated controls in the presence or absence of pro-survival BCL-2 overexpression	26447190
HH and Hut78 cells	Proliferation assay	10 μM	0, 24, 48, 72 h	DMSO	Both cell lines were sensitive to treatment with 10 μM 966. However, Hut78 cells exhibited a greater sensitivity than HH cells.	23894374
HH	Function assay	10 μM	24 h	DMSO	increases the acetylation at H3K9/K14, H3K27, and H4K5	23894374
Hut78	Function assay	10 μM	24 h	DMSO	increases the acetylation at H3K9/K14, H3K27, and H4K5	23894374
HL60	Antiproliferative assay		48 hrs		Antiproliferative activity against human HL60 cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay, IC50 = 1.64 μM.	29940115
K562	Antiproliferative assay		48 hrs		Antiproliferative activity against human K562 cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay, IC50 = 1.64 μM.	29940115
HEL	Antiproliferative assay		48 hrs		Antiproliferative activity against human HEL cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay, IC50 = 1.64 μM.	29940115
HL60	Antiproliferative assay		48 hrs		Antiproliferative activity against human HL60 cells after 48 hrs by CCK-8 assay, IC50 = 21.71 μM.	29940115
K562	Antiproliferative assay		48 hrs		Antiproliferative activity against human K562 cells after 48 hrs by CCK-8 assay, IC50 = 21.71 μM.	29940115
HEL	Antiproliferative assay		48 hrs		Antiproliferative activity against human HEL cells after 48 hrs by CCK-8 assay, IC50 = 21.71 μM.	29940115
Sf9	Function assay		60 mins		Inhibition of full length human C-terminal His-tagged HDAC3/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in baculovirus infected Sf9 insect cells using substrate measured after 60 mins by colorimetric method	29541372
Click to View More Cell Line Experimental Data

Biological Activity

Description

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.

Targets

HDAC3 ^[1]
(Cell-free assay)

80 nM

In vitro
In vitro	RGFP966 is a slow-on/slow-off, competitive tight-binding HDAC inhibitor, with an IC50 of 0.08μM for HDAC3 and no effective inhibition of any other HDAC at concentrations up to 15μM. ^[1] RGFP966 treatment on two CTCL cell lines for 24 hours prior to western blot analysis resulted in increased acetylation at H3K9/K14, H3K27, and H4K5, but not H3K56ac. RGFP966 decreases cell growth in CTCL (cutaneous T cell lymphoma) cell lines due to increased apoptosis that is associated with DNA damage and impaired S phase progression. RGFP966 causes a significant reduction in DNA replication fork velocity within the first hour of drug treatment. ^[2]
Kinase Assay	Deacetylation assays
Kinase Assay	Deacetylation assays are based on the homogenous fluorescence release assay. Purified recombinant enzymes are incubated with serial-diluted inhibitors at the concentrations indicated in the figures, with pre-incubation times ranging from 0 to 3 hours, in the standard HDAC buffer. Acetyl-Lys(Ac)-AMC substrate (at 10 μM, corresponding to the Km for both HDAC1 and HDAC3) is added after the pre-incubation period. The reaction is allowed to run for 1 hour. The trypsin peptidase developer, at final concentration of 5mg/ml, is added after 1 hour, and the fluorescence emission is then measured using a Tecan M200 96-well plate reader.
Cell Research	Cell lines	HH and Hut78 CTCL cell lines
	Concentrations	~10μM
	Incubation Time	24 to 72 h
	Method	Cells are counted and split into T25 (Corning) flasks at 26105 cells/mL. Cells are then treated with DMSO, or HDIs once at hour 0. 100 ml aliquots are taken in triplicate from each flask at 0 hr, 24 hrs, 48 hrs, and 72 hrs after treatment, distributed into a flat bottom 96-well plate, and 10 ml of alamar blue added to each well. After a 4 hr incubation, fluorescence is measured using the Biotek Synergy MX Microplate Reader.
Experimental Result Images	Methods	Biomarkers	Images	PMID
Experimental Result Images	Western blot	p-STAT3 / Acetyl-STAT3 / STAT3 / Ac-H3 / Ac-H4 H3K9K14ac / H3 / H3K56ac / H3K27ac / H4K5ac		28338101

In Vivo
In vivo	RGFP966 treatment (10 mg/kg) enhances long-term memory for object memory. RGFP966 (3 or 10 mg/kg, s.c.) facilitates extinction and prevents reinstatement of cocaine- conditioned place preference. ^[1]
Animal Research	Animal Models	Mouse
	Dosages	10 mg/kg, 10.0 mL/kg
	Administration	s.c.

References
[1] Malvaez M, et al. PNAS, 2013, 110(7), 2647-2652. [2] Wells CE, et al. PLoS One, 2013, 8(7), e68915.

References

Chemical Information & Solubility

Molecular Weight	362.4	Formula	C₂₁H₁₉FN₄O
CAS No.	1396841-57-8	SDF	Download RGFP966 SDF
Smiles	C1=CC=C(C=C1)C=CCN2C=C(C=N2)C=CC(=O)NC3=C(C=C(C=C3)F)N
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 72 mg/mL ( (198.67 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molecular Weight Calculator

In vivo Batch: Add solvents to the product individually and in order.					In vivo Formulation Calculator
	Clear solution	10%DMSO 1 40%PEG300 2 5%Tween80 3 45%ddH2O	5.0mg/ml (13.80mM)	Taking the 1 mL working solution as an example, add 100 μL of 50 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 450 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.	In vivo Formulation Calculator
Clear solution	5%DMSO 1 Corn oil	3.6mg/ml (9.93mM)	Taking the 1 mL working solution as an example, add 50 μL of 72 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Clear solution	5%DMSO 1 40%PEG300 2 10%Tween80 3 45%ddH2O	3.6mg/ml (9.93mM)	Taking the 1 mL working solution as an example, add 50 μL of clarified DMSO stock solution of 72 mg/ml to 400 μL of PEG300, mix evenly to clarify it; add 100 μL of Tween80 to the above system, mix evenly to clarify it; then continue to add 450 μL of ddH2O to make it clear. Volume up to 1 mL. The mixed solution should be used immediately for optimal results.

Preparing Stock Solutions

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
Does this product S7229 specifically inhibit HDAC3? Or does it target other HDACs as well?

Answer:
In the paper, it is indicated that "RGFP966 is specific for HDAC3, with an IC50 of 0.08 μM and no effective inhibition of any other HDAC at concentrations up to 15 μM. ". However, we did not preform experiment to confirm this data. Please refer to the following link for detailed information: http://www.pnas.org/content/110/7/2647.long

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):